(Q38238548)

31 August 2017

title

Fostering adherence to injectable disease-modifying therapies in multiple sclerosis (English)

1 reference

31 August 2017

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109614%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Maria Rosa Rottoli

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109614%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Francesco Patti

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109614%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

11 August 2014

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109614%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109614%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109614%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

1029-1042

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109614%20AND%20SRC:MED&resulttype=core&format=json

Treatment of cognitive impairment in patients with multiple sclerosis

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Mortality in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Not to be taken as directed

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Medication compliance and persistence: terminology and definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Unintentional non-adherence to chronic prescription medications: how unintentional is it really?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Stoppers and non-starters of disease-modifying treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Risk factors for and management of cognitive dysfunction in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Is speed of processing or working memory the primary information processing deficit in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Information processing efficiency in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

An examination of suicidal intent in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

The Goldman Consensus statement on depression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Self-report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: a systematic review of measurement properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Management options in multiple sclerosis-associated fatigue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Moving towards the pan-European unification of multiple sclerosis nurses: a consensus paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

The impact of a patient support program for multiple sclerosis on patient satisfaction and subjective health status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

The role of the clinical nurse specialist in MS: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Preferred sources of health information in persons with multiple sclerosis: degree of trust and information sought

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Factors that influence adherence with disease-modifying therapy in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Design of an mHealth app for the self-management of adolescent type 1 diabetes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Adherence to a smartphone application for weight loss compared to website and paper diary: pilot randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

'Gamification': influencing health behaviours with games.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Prevalence and correlates of exergaming in youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Home-based balance training using the Wii balance board: a randomized, crossover pilot study in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Furthering patient adherence: a position paper of the international expert forum on patient adherence based on an internet forum discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.945523